Pediatric Oncology

Sixty percent of adult survivors of pediatric CNS tumors do not achieve full functional and social independence, according to results from a study conducted by researchers at St. Jude Children’s Research Hospital and the University of Tennessee Health Science Center.

James I. Geller, MD, describes the ongoing work in pediatric patients with rare rhabdoid tumors.

Kristopher R. Bosse, MD, discusses how D3-GPC2-PBD could impact pediatric neuroblastoma.

Benjamin A. Youngblood, PhD, assistant member, Department of Immunology, St. Jude Children’s Research Hospital, discusses the impact of T-cell differentiation and exhaustion in pediatric cancer.

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses a trial of tazemetostat in pediatric patients with INI1-negative tumors.

Kristopher Bosse, MD, attending physician, Division of Oncology, The Children's Hospital of Philadelphia, discusses challenges with immunotherapy in pediatric cancers.

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses the treatment of pediatric patients with sarcoma.

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses integrating palliative care into the treatment of pediatric oncology.

Brian D. Crompton, MD, provides insight on the debate of liquid versus tissue biopsies, particularly in the setting of pediatric patients with sarcomas.

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses developing drugs for children with cancer.

Susan N. Chi, MD, senior physician, director, Pediatric Brain Tumor Clinical Trials Program, Dana-Farber Cancer Institute, assistant professor of pediatrics, Harvard Medical School, discusses pediatric atypical teratoid rhabdoid tumors.

Ami Vijay Desai, MD, discusses the ideal patient population for entrectinib and what the future could hold for the agent.

Kelly Bailey, MD, PhD, physician, department of Pediatric Hematology/Oncology, Children's Hospital of Pittsburgh, University of Pittsburgh Medical Center, discusses clinical needs in pediatric patients with bone sarcoma.

Justin N. Baker, MD, chief, Division of Quality of Life and Palliative Care, attending physician, Quality of Life Service, St. Jude Children’s Research Hospital, discusses approaching palliative care for children with cancer.

Santhosh A. Upadhyaya, MD, discusses how chemotherapy prior to radiation can improve cure rates, the importance of long-term follow-up in this patient population, and emerging research and treatment for pediatric ependymoma.

Matthew Ladra, MD, director, Pediatric Radiation Oncology, Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital, discusses the treatment of esthesioneuroblastoma in children.

The FDA has approved the combination of nivolumab and ipilimumab for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

Michael Link, MD, Lydia J. Lee Professor in Pediatric Cancer, professor, Pediatrics, Stanford Cancer Institute, and a 2018 Giant of Cancer Care in Pediatric Oncology, discusses the randomized trial testing nelarabine in patients with T-cell malignancies.

The European Commission has approved dasatinib for the treatment of children and adolescent patients aged 1 to 18 years with Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of tisagenlecleucel for the treatment of either adult patients with diffuse large B-cell lymphoma that is relapsed or refractory after 2 or more lines of systemic therapy, or patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse posttransplant, or in second or later relapse.

Justin N. Baker, MD, discusses the benefits of a holistic approach to end-of-life care in pediatric oncology, as well as the importance of teaching palliative care to the next generation of oncologists and hematologists.

The FDA has granted an accelerated approval to pembrolizumab for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma, or those who have relapsed after 2 or more prior lines of therapy.

Briana Patterson, MD, assistant professor, Division of Endocrinology, Aflac Cancer Center, Department of Pediatrics, Emory University School of Medicine, discusses the use of tyrosine kinase inhibitors in the treatment of patients with chronic myeloid leukemia.

All 3 patients with targeted gene fusions responded to the multikinase inhibitor entrectinib, according to a phase I study in children and young adults with advanced, previously treated central nervous system tumors.

A course of low-dose maintenance chemotherapy administered after standard-of-care intensive chemotherapy led to significant improvements in disease-free and overall survival in pediatric rhabdomyosarcoma.

Birte Wistinghausen, MD, associate professor, Pediatrics, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses targeted therapies for the treatment of pediatric patients with non-Hodgkin lymphoma.

The FDA has granted a priority review to a supplemental new drug application for eltrombopag (Promacta) for use in combination with standard immunosuppressive therapy as a frontline treatment for patients with severe aplastic anemia.

Susan N. Chi, MD, discusses the rationale for using tazemetostat in pediatric patients with INI1-negative rhabdoid tumors, as well as the future steps being taken with this treatment.

The FDA has granted crizotinib a breakthrough therapy designation for the treatment of patients with metastatic non–small cell lung cancer with MET exon 14 alterations, and for use in patients with relapsed/refractory ALK+ anaplastic large cell lymphoma.

Lindsay Frazier, MD, institute physician, Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, associate professor of pediatrics, Harvard Medical School, discusses the Malignant Germ Cell International Consortium (MaGIC) in pediatric and rare tumors.